This result refutes another (retracted) conclusion in the Fissi paper: “Our data also indicate that anti-fission or pro-fusion drugs, envisioned as treatments for CMT2A or neurodegenerative disease, could be detrimental for patients with R364W and L76P alleles that would rather benefit from the development of pro-fission or anti-fusion molecules.” [30]. Here, MFN2 is linked to neurodegenerative disease.